A 57-year-old female was diagnosed as local, lung, and multiple liver metastases in the 2 years and 6 months after surgery. As expression of HER2 showed 3+, we performed trastuzumab/paclitaxel combination therapy. After 3 cycles, a rapid complete response was seen clinically. It is suggested that trastuzumab/paclitaxel combination therapy might be a first-line treatment for HER2 overexpressing recurrent breast cancer which had not been treated previously with anthracycline drugs.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Clinicopathological analysis of claudin 18.2 focusing on intratumoral heterogeneity and survival in patients with metastatic or unresectable gastric cancer.
ESMO Open
December 2024
Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; Department of Interdisciplinary Program in Cancer Biology, Seoul National University College of Medicine, Seoul, Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. Electronic address:
Background: This study aimed to investigate the prevalence of claudin 18.2 (CLDN18.2) positivity, with a particular focus on intratumoral heterogeneity, and its association with clinicopathological features in metastatic or unresectable gastric cancer (GC).
View Article and Find Full Text PDFComprehensive Evaluation of Cancer Treatment-Related Cardiac Dysfunction by Ultrasound Myocardial Strain: A Network Meta-Analysis.
Cardiol Rev
October 2023
From the Department of Cardiovascular Ultrasound, The People's Hospital of China Medical University and The People's Hospital of Liaoning Province, Shenyang, China.
Anticancer treatment regimens are effective but may lead to cardiac dysfunction. The meaning of this statement is that myocardial strain can be a good indicator of cancer treatment-related cardiac dysfunction. We used Bayesian network meta-analysis to compare and rank these regimens to comprehensively evaluate their influence on the heart.
View Article and Find Full Text PDFPharmacovigilance Analysis of Heart Failure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer.
JACC CardioOncol
February 2023
Division of Oncology, Stanford University School of Medicine, Palo Alto, California, USA.
Article Synopsis
- Trastuzumab, a treatment for HER2-overexpressing cancers, is linked to higher risks of heart failure (HF), particularly when compared to other anti-HER2 therapies.
- A study analyzed data from nearly 42,000 patients to compare the incidence of heart failure across various anti-HER2 treatments, including monoclonal antibodies, antibody-drug conjugates, and tyrosine kinase inhibitors.
- The results indicated that trastuzumab had significantly higher odds of heart failure reports compared to other anti-HER2 therapies, with the highest risks being associated with the combination therapy of trastuzumab and pertuzumab.
Survival outcomes with 12 weeks of adjuvant or neoadjuvant trastuzumab in breast cancer.
Indian J Cancer
November 2022
Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
Background: There is limited access to 1 year of adjuvant trastuzumab in resource-constrained settings. Most randomized studies have failed to prove non-inferiority of shorter durations of adjuvant trastuzumab compared to 1 year However, shorter durations are often used when 1 year is not financially viable. We report the outcomes with 12 weeks of trastuzumab administered as part of curative-intent treatment.
View Article and Find Full Text PDFResponse to trastuzumab and investigation of expression profiles of matrix metalloproteinase-related proteins in primary breast cancer stem cells.
Clin Exp Med
August 2021
Meram Faculty of Medicine, Department of Medical Oncology, Necmettin Erbakan University, Konya, Turkey.
Breast cancer (BC) is the leading cause of cancer deaths in women. One of the reasons for the failure of BC treatment is reportedly the ineffectiveness of chemotherapeutic drugs against breast cancer stem-like cells (BCSCs). HER2 receptors have an important role in the self-renewal of BCSCs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!